Stalfort John A III 4
4 · Verrica Pharmaceuticals Inc. · Filed Nov 26, 2024
Insider Transaction Report
Form 4
Stalfort John A III
Director
Transactions
- Purchase
Common Stock
2024-11-22+1,123,595→ 1,823,800 total - Purchase
Series B Warrants (right to buy)
2024-11-22+561,797→ 561,797 totalExercise: $1.33From: 2024-11-22Exp: 2029-11-22→ Common Stock (561,797 underlying) - Gift
Common Stock
2024-11-26+50,000→ 1,873,800 total - Purchase
Series A Warrants (right to buy)
2024-11-22+561,797→ 561,797 totalExercise: $1.07From: 2024-11-22Exp: 2025-11-22→ Common Stock (561,797 underlying)
Footnotes (1)
- [F1]The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.